Last reviewed · How we verify

NCT06727084

Serum Albumin in Acute Coronary Syndrome

Not yet recruiting Last updated 4 July 2025
What this trial tests

trial in Acute Coronary Syndrome in 40 participants. Not yet recruiting.

Timeline
1 January 2026
Primary endpoint
1 April 2026
1 May 2026

Quick facts

Lead sponsorSohag University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment40
Start date1 January 2026
Primary completion1 April 2026
Estimated completion1 May 2026
Sites1 location across Egypt

Conditions studied

Sponsor

Sohag University

Who can join

18 and older, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study aims to investigate the predictive value of serum albumin and short-term mortality in patients with Acute Coronary Syndrome (ACS)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06727084.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing